Bavarian Nordic lowers guidance on manufacturing delay

Bavarian Nordic A/S (CSE:BAVA) lowered its 2010 revenue guidance to DKK325 million ($55.5 million) from DKK475 million ($81.2 million) after a technical issue delayed manufacturing scale-up of its Imvamune smallpox vaccine. The company, which primarily derives its revenue from deliveries of Imvamune to the U.S. Strategic National Stockpile, said it now plans to ship a total of 2 million doses in 2010 instead of a previously expected 4-5 million doses. The company said it has taken corrective actions. Bavarian Nordic reported 1H10 revenues of DKK175 ($29.9 million). ...